HIV: cell binding and entry.

The first step of the human immunodeficiency virus (HIV) replication cycle-binding and entry into the host cell-plays a major role in determining viral tropism and the ability of HIV to degrade the human immune system. HIV uses a complex series of steps to deliver its genome into the host cell cytoplasm while simultaneously evading the host immune response. To infect cells, the HIV protein envelope (Env) binds to the primary cellular receptor CD4 and then to a cellular coreceptor. This sequential binding triggers fusion of the viral and host cell membranes, initiating infection. Revealing the mechanism of HIV entry has profound implications for viral tropism, transmission, pathogenesis, and therapeutic intervention. Here, we provide an overview into the mechanism of HIV entry, provide historical context to key discoveries, discuss recent advances, and speculate on future directions in the field.

[1]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[2]  C. Hill,et al.  Design of a Potent d-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance , 2010, Journal of Virology.

[3]  Bradley C. Lowekamp,et al.  3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells , 2010, Proceedings of the National Academy of Sciences.

[4]  P. Love,et al.  ITAM-mediated signaling by the T-cell antigen receptor. , 2010, Cold Spring Harbor perspectives in biology.

[5]  L. Ratner,et al.  Role of Abl Kinase and the Wave2 Signaling Complex in HIV-1 Entry at a Post-Hemifusion Step , 2010, PLoS pathogens.

[6]  Michael Loran Dustin,et al.  HIV-1 Virological Synapse is not Simply a Copycat of the Immunological Synapse , 2010, Viruses.

[7]  R. Varma,et al.  Immunological synapse: a multi‐protein signalling cellular apparatus for controlling gene expression , 2010, Immunology.

[8]  W. Mothes,et al.  Directional Spread of Surface-Associated Retroviruses Regulated by Differential Virus-Cell Interactions , 2010, Journal of Virology.

[9]  R. Kaul,et al.  The integrin α4β7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1 , 2009, Proceedings of the National Academy of Sciences.

[10]  Yuntao Wu,et al.  Chemokine Coreceptor Signaling in HIV-1 Infection and Pathogenesis , 2009, PLoS pathogens.

[11]  M. Parmentier,et al.  Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the Protean Effects of “Selective” Antagonists* , 2009, The Journal of Biological Chemistry.

[12]  Michael Loran Dustin,et al.  Human Immunodeficiency Virus Type 1 Envelope gp120-Induced Partial T-Cell Receptor Signaling Creates an F-Actin-Depleted Zone in the Virological Synapse , 2009, Journal of Virology.

[13]  Walther Mothes,et al.  HIV Entry Revisited , 2009, Cell.

[14]  G. Melikyan,et al.  HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes , 2009, Cell.

[15]  Frank Y. S. Chuang,et al.  Quantitative 3D Video Microscopy of HIV Transfer Across T Cell Virological Synapses , 2009, Science.

[16]  G. Melikyan,et al.  Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm , 2008, Retrovirology.

[17]  L. Dong,et al.  HIV Envelope-CXCR4 Signaling Activates Cofilin to Overcome Cortical Actin Restriction in Resting CD4 T Cells , 2008, Cell.

[18]  Jianping Liu,et al.  Human Immunodeficiency Virus Type 1 Envelope gp120 Induces a Stop Signal and Virological Synapse Formation in Noninfected CD4+ T Cells , 2008, Journal of Virology.

[19]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[20]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[21]  Eva Chung,et al.  HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells , 2008, Nature Immunology.

[22]  Michael S. Kay,et al.  Potent D-peptide inhibitors of HIV-1 entry , 2007, Proceedings of the National Academy of Sciences.

[23]  R. Steinman,et al.  The interaction of HIV with dendritic cells: outcomes and pathways , 2007, Trends in Immunology.

[24]  Marc Parmentier,et al.  Allosteric Transinhibition by Specific Antagonists in CCR2/CXCR4 Heterodimers* , 2007, Journal of Biological Chemistry.

[25]  Wei Huang,et al.  Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations , 2007, Journal of Virology.

[26]  Robin Shattock,et al.  Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? , 2006, Nature Reviews Microbiology.

[27]  Mark Marsh,et al.  Virus Entry: Open Sesame , 2006, Cell.

[28]  J. Bergelson,et al.  Virus-Induced Abl and Fyn Kinase Signals Permit Coxsackievirus Entry through Epithelial Tight Junctions , 2006, Cell.

[29]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[30]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[31]  Nathan M. Sherer,et al.  Actin- and myosin-driven movement of viruses along filopodia precedes their entry into cells , 2005, The Journal of cell biology.

[32]  Don C. Wiley,et al.  Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.

[33]  Oliver Hartley,et al.  V3: HIV's switch-hitter. , 2005, AIDS research and human retroviruses.

[34]  K. Subbarao,et al.  pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN , 2004, Journal of Virology.

[35]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[36]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[37]  D. McDonald,et al.  Recruitment of HIV and Its Receptors to Dendritic Cell-T Cell Junctions , 2003, Science.

[38]  R. Gorlin,et al.  Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.

[39]  Mitsuhiro Osame,et al.  Spread of HTLV-I Between Lymphocytes by Virus-Induced Polarization of the Cytoskeleton , 2003, Science.

[40]  Gregory J Babcock,et al.  Ligand-independent Dimerization of CXCR4, a Principal HIV-1 Coreceptor* , 2003, The Journal of Biological Chemistry.

[41]  R. Doms,et al.  Diversity of receptors binding HIV on dendritic cell subsets , 2002, Nature Immunology.

[42]  Michael Loran Dustin,et al.  The immunological synapse , 2002, Arthritis research.

[43]  P. Gallay,et al.  Syndecans Serve as Attachment Receptors for Human Immunodeficiency Virus Type 1 on Macrophages , 2001, Journal of Virology.

[44]  P. Charneau,et al.  The Maturation of Dendritic Cells Results in Postintegration Inhibition of HIV-1 Replication1 , 2001, The Journal of Immunology.

[45]  R. Paranjape,et al.  Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. , 2000, Virology.

[46]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[47]  P. S. Kim,et al.  Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.

[48]  P. Vernazza,et al.  Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.

[49]  Q. Sattentau,et al.  HIV-1 attachment: another look. , 1999, Trends in microbiology.

[50]  C. Acquaviva,et al.  The Protein Tyrosine Kinase p56lck Is Required for Triggering NF-κB Activation upon Interaction of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 with Cell Surface CD4 , 1998, Journal of Virology.

[51]  D. Ho,et al.  Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. , 1998, Virology.

[52]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[53]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[54]  M. Locati,et al.  HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. , 1997, Virology.

[55]  M. Moroni,et al.  Homozygous Δ32 deletion of the CCR‐5 chemokine receptor gene in an HIV‐1‐infected patient , 1997 .

[56]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[57]  M. Goldsmith,et al.  Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[58]  C. Katlama,et al.  HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. , 1997, Lancet.

[59]  C. Winkler,et al.  HIV-1 infection in a man homozygous for CCR5▵32 , 1997, The Lancet.

[60]  C. Katlama,et al.  HIV-1 infection in an individual homozygous for CCR5▵32 , 1997, The Lancet.

[61]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[62]  J. Sodroski,et al.  HIV-1 Entry and Macrophage Inflammatory Protein-1β-mediated Signaling Are Independent Functions of the Chemokine Receptor CCR5* , 1997, The Journal of Biological Chemistry.

[63]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[64]  A. Garzino-Demo,et al.  The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection , 1996, Nature Medicine.

[65]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[66]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[67]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[68]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[69]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[70]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[71]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[72]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[73]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[74]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[75]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[76]  S. Warren,et al.  Translational suppression by trinucleotide repeat expansion at FMR1 , 1995, Science.

[77]  B. Sykes,et al.  Structure‐activity relationships of chemokines , 1995, Journal of leukocyte biology.

[78]  L. Stamatatos,et al.  Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. , 1995, Virology.

[79]  K. Jeang,et al.  The cytoplasmic domain of CD4 plays a critical role during the early stages of HIV infection in T‐cells. , 1994, The EMBO journal.

[80]  L. Stamatatos,et al.  CD26 is not involved in infection of peripheral blood mononuclear cells by HIV-1. , 1994, AIDS.

[81]  Q. Sattentau,et al.  Factors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26 , 1994, Journal of virology.

[82]  M. Wainberg,et al.  Association of p56lck with the cytoplasmic domain of CD4 modulates HIV‐1 expression. , 1994, The EMBO journal.

[83]  E. Jacotot,et al.  T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. , 1993, Science.

[84]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[85]  A. Fischer,et al.  Human immunodeficiency virus gp120 and derived peptides activate protein tyrosine kinase p56Ick in human CD4 T lymphocytes , 1993, European journal of immunology.

[86]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[87]  K Inaba,et al.  Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. , 1992, Science.

[88]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[89]  S. Kassis,et al.  Effect of human immunodeficiency virus gp120 glycoprotein on the association of the protein tyrosine kinase p56lck with CD4 in human T lymphocytes. , 1991, The Journal of biological chemistry.

[90]  G. Orloff,et al.  Penetration of CD4 T cells by HIV-1. The CD4 receptor does not internalize with HIV, and CD4-related signal transduction events are not required for entry. , 1991, Journal of immunology.

[91]  Lange,et al.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates , 1989, Journal of virology.

[92]  R. Axel,et al.  HIV infection does not require endocytosis of its receptor, CD4 , 1988, Cell.

[93]  Q. Sattentau,et al.  The CD4 antigen: Physiological ligand and HIV receptor , 1988, Cell.

[94]  M. Marsh,et al.  Human immunodeficiency virus infection of CD4‐bearing cells occurs by a pH‐independent mechanism. , 1988, The EMBO journal.

[95]  Edgar G. Engleman,et al.  pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane , 1987, Cell.

[96]  Robin A. Weiss,et al.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.

[97]  J K Nicholson,et al.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. , 1986, Science.

[98]  C. Griscelli,et al.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. , 1984, Science.

[99]  M. Gottlieb,et al.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. , 1981, The New England journal of medicine.

[100]  R. Doms,et al.  Entry inhibitors in the treatment of HIV-1 infection. , 2010, Antiviral research.

[101]  Jianping Liu,et al.  Human Immunodeficiency Virus Type 1 Envelope gp120 Induces a Stop Signal and Virological Synapse Formation in Noninfected CD4+ T Cells , 2008, Journal of Virology.

[102]  A. Fischer,et al.  Human immunodeficiency virus gp120 and derived peptides activate protein tyrosine kinase p56lck in human CD4 T lymphocytes. , 1993, European journal of immunology.